Table Graph
      published meta-analysis   sensitivity analysis   studies

janus kinase (JAK) inhibitor in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsTziolos, 2021 0.93 [0.87; 0.99] 0.93[0.87; 0.99]Tziolos, 202110%369NAnot evaluable deathsdetailed resultsTziolos, 2021 0.47 [0.28; 0.80] 0.47[0.28; 0.80]Tziolos, 202110%369NAnot evaluable ICU admissiondetailed resultsTziolos, 2021 0.19 [0.10; 0.39] 0.19[0.10; 0.39]Tziolos, 202110%369NAnot evaluable acute kidney injury detailed resultsTziolos, 2021 0.43 [0.14; 1.34] 0.43[0.14; 1.34]Tziolos, 202110%369NAnot evaluable arrhythmiadetailed resultsTziolos, 2021 0.16 [0.03; 0.90] 0.16[0.03; 0.90]Tziolos, 202110%369NAnot evaluable elevated liver enzymesdetailed resultsTziolos, 2021 0.52 [0.18; 1.51] 0.52[0.18; 1.51]Tziolos, 202110%369NAnot evaluable Myocardial infarction detailed resultsTziolos, 2021 0.87 [0.19; 3.92] 0.87[0.19; 3.92]Tziolos, 202110%369NAnot evaluable venous thromboembolism detailed resultsTziolos, 2021 5.23 [0.42; 65.62] 5.23[0.42; 65.62]Tziolos, 202110%369NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-23 12:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 1046,727,818,606,954,964,962,963,1045 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons